Ignite Creation Date:
2024-05-05 @ 11:39 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00100477
Status:
COMPLETED
Last Update Posted:
2013-09-25
First Post:
2004-12-30
Brief Title:
Use of Topotecan in Patients With Refractory Acute Leukemia
Sponsor:
US Department of Veterans Affairs
Organization:
VA Office of Research and Development
Study Overview
Official Title:
Study of Topoisomerase Inhibition in the Treatment of Acute Leukemia
Status:
COMPLETED
Status Verified Date:
2013-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to identify the highest tolerated doses in drugs used to treat aggressive leukemia lymphoma or multiple myeloma not responding to standard chemotherapy treatment The drugs being used in this study include drugs frequently used in treating such diseases mitoxantrone and etoposide as well as a newer drug that has also been shown to be effective topotecan
Detailed Description:
The purpose of this study is to identify the highest tolerated doses in drugs used to treat aggressive leukemia lymphoma or multiple myeloma not responding to standard chemotherapy treatment The drugs being used in this study include drugs frequently used in treating such diseases mitoxantrone and etoposide as well as a newer drug that has also been shown to be effective topotecan
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None